Zentalis Pharmaceuticals

What Zentalis Pharmaceuticals does

Zentalis Pharmaceuticals is a clinical-stage biopharmaceutical company developing azenosertib (ZN-c3), an investigational highly selective oral WEE1 kinase inhibitor designed as a non-chemotherapy, biomarker-driven therapy for Cyclin E1-positive platinum-resistant ovarian cancer (PROC). WEE1 inhibition blocks a key DNA damage response regulator, forcing cancer cells with unrepaired DNA damage into premature mitosis and cell death while largely sparing healthy cells. The company's clinical program includes the registration-intent DENALI Phase 2 trial and the ASPENOVA Phase 3 trial versus standard-of-care chemotherapy, alongside the MUIR Phase 1 trial evaluating combinations with chemotherapy and bevacizumab. A proprietary immunohistochemistry companion diagnostic with a defined Cyclin E1 cutoff is being co-developed to identify the approximately 50% of PROC patients who overexpress Cyclin E1 and may benefit most from azenosertib monotherapy. Preclinical evidence presented at AACR 2026 also supports potential expansion into triple-negative breast cancer via ADC combinations.

The company is publicly traded on NASDAQ under ticker ZNTL, headquartered in San Diego with a distributed remote workforce of 101–250 employees, and operates as Zentalis Pharmaceuticals, Inc., a Delaware corporation founded in 2014. Zentalis is pre-revenue; access to azenosertib is currently provided exclusively through clinical trials, and the firm is building commercial infrastructure, including a newly appointed SVP of Commercial Strategy and a board member with deep oncology launch experience, in anticipation of potential regulatory approval. Capital base includes a $25 million Pfizer strategic equity investment (April 2022) and two subsequent underwritten offerings totaling approximately $450 million (May 2022 and June 2023), with $211.8 million in cash as of Q1 2026 providing runway into late 2027. Azenosertib has received FDA Fast Track Designation for Cyclin E1-positive PROC, and ASPENOVA Phase 3 topline data are expected by year-end 2026.

Name

Zentalis Pharmaceuticals

Legal name

Zentalis Pharmaceuticals, Inc.

Website

https://zentalis.com

Company type

Public

Founded year

2014

Operating status

Operating

Headcount range

101–250 employees

Short description

Zentalis Pharmaceuticals is a clinical-stage biopharmaceutical company developing azenosertib, an investigational oral WEE1 kinase inhibitor for Cyclin E1-positive platinum-resistant ovarian cancer, paired with a proprietary companion diagnostic and registration-intent Phase 2 and Phase 3 trials underway.

Ownership category

akta.pro rank

Product category

Oncology Therapeutics

NAICS

Research and Development in Biotechnology (except Nanobiotechnology) (541714), Pharmaceutical Preparation Manufacturing (325412)

SIC

Pharmaceutical Preparations (2834)

akta.pro primary industry

Clinical Development (Phase I–III Trial Design & Execution) (HLAIALAE)

Keywords

• Oncology drug development
• WEE1 kinase inhibitors
• Ovarian cancer therapy
• Clinical stage biopharmaceuticals
• Precision cancer medicine

Headquarters

HQ city

New York

HQ country

United States

HQ region

North America

Offices1 record

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Personnel, Operations

Revenue model

1. Pharmaceutical Product Sales: Zentalis is a clinical-stage biopharmaceutical company focused on developing azenosertib for the treatment of Cyclin E1-positive platinum-resistant ovarian cancer. If approved, the company intends to commercialize the drug directly, with commercial infrastructure being built in anticipation of potential launch. Revenue will be generated through prescription drug sales to healthcare providers and patients.

Go-to-market motion1 record

Distribution channels3 records

Marketing channels8 records

Core offering

Zentalis Pharmaceuticals is a clinical-stage biopharmaceutical company developing azenosertib (ZN-c3), an investigational oral, non-chemotherapy, biomarker-driven WEE1 kinase inhibitor targeting Cyclin E1-positive platinum-resistant ovarian cancer. The company is advancing registration-intent studies (DENALI Phase 2 and ASPENOVA Phase 3) and developing a proprietary companion diagnostic (IHC assay) to identify eligible patients based on Cyclin E1 protein overexpression.

Product overview

Zentalis Pharmaceuticals is a clinical-stage biopharmaceutical company developing azenosertib (ZN-c3), an investigational first-in-class highly selective WEE1 kinase inhibitor as an oral, non-chemotherapy, biomarker-driven therapy. The company's focused pipeline centers on azenosertib as monotherapy for Cyclin E1-positive platinum-resistant ovarian cancer, with registration-intent studies DENALI (Phase 2) and ASPENOVA (Phase 3), alongside combination therapy studies in the MUIR trial. A companion diagnostic is being developed to identify eligible patients based on Cyclin E1 protein overexpression.

Differentiator

Problem solved

Functional benefit

Products and services

• Azenosertib (ZN-c3) Azenosertib (ZN-c3) is an investigational highly selective WEE1 kinase inhibitor being developed as an oral, non-chemotherapy, biomarker-driven therapy for Cyclin E1-positive platinum-resistant ovarian cancer. Designed for once-daily oral dosing at home, it inhibits WEE1 to force cancer cells with unrepaired DNA damage into premature mitosis, leading to cell death while largely sparing healthy cells.
• Companion Diagnostic for Cyclin E1 An immunohistochemistry (IHC) clinical assay with proprietary cutoff designed to identify platinum-resistant ovarian cancer patients whose tumors overexpress Cyclin E1 protein and are therefore most likely to benefit from azenosertib monotherapy.

Quantifiable outcome

• 39.1% objective response rate in platinum-resistant ovarian cancer patients treated with azenosertib plus paclitaxel (46 patients in MUIR Phase 1b trial)
• +4 more outcomes

Segments3 records

Ideal customer profiles2 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature4 records

Scale indicators9 records

Recent moves6 records

Expansion highlights5 records

Emerging players

• Repare Therapeutics: Synthetic lethality-focused oncology company working on DNA damage response targets (including WEE1-adjacent mechanisms) with similar biomarker-stratified clinical development approach.
• Schrödinger: Computational drug discovery platform with oncology programs in clinical development; comparable clinical-stage oncology footprint and similar partnership-driven development model.
• Werewolf Therapeutics: Clinical-stage oncology company developing targeted cytokine-based therapies; comparable size and clinical-stage development profile with similarly limited product revenue.

Direct peers

• Mersana Therapeutics: Clinical-stage oncology company developing antibody-drug conjugates for ovarian cancer and other solid tumors; comparable size, late-stage clinical profile, and focus on targeted oncology therapeutics.
• Black Diamond Therapeutics: Precision oncology company developing allosteric kinase inhibitors across multiple oncogenic targets; comparable clinical-stage profile and biomarker-driven development approach, and Zentalis board member Dave Johnson also serves on Black Diamond's board.
• Theseus Pharmaceuticals: Clinical-stage precision oncology company developing kinase inhibitors (including pan-EGFR) for treatment-resistant cancers; similar business model of developing biomarker-driven targeted therapies with no approved products.
• Verastem Oncology: Late-stage oncology company developing VS-6766 (RAF/MEK inhibitor) in recurrent low-grade serous ovarian cancer; comparable clinical-stage ovarian cancer company with similar patient population and combination-therapy positioning.
• ImmunoGen (AbbVie): Developed Elahere (mirvetuximab soravtansine), the first targeted ADC approved for platinum-resistant ovarian cancer — directly competes with azenosertib for the same PROC patient population and defines the competitive benchmark azenosertib must beat.

Broad incumbents

• Pfizer: Major oncology pharma that made a $25M strategic equity investment in Zentalis and collaborated on azenosertib clinical development; owns Seagen and Harpoon assets and represents both a key strategic investor and a likely acquirer for late-stage oncology assets.
• AstraZeneca: Major pharma with a broad oncology pipeline including the historic adavosertib (AZD1775) WEE1 program and active development in ovarian cancer (Lynparza); represents the competitive benchmark and potential partnership/acquisition counterparty for WEE1-class development.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks7 records

Key highlights7 records

Customer concentration

• LinkedInlinkedin.com/company/zentalis-pharmaceuticals
• Xx.com/ZentalisP
• Facebookfacebook.com/zentalispharma

Revenue estimate

Valuation estimate

Number of profiles

Profiles14 records

Funding overview

Funding rounds9 records

Investors9 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Zentalis Pharmaceuticals